Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

 
• By Joseph Haas
Coronavirus globe
Gilead's retrospective analysis of remdesivir needs to be backed up by a traditional study

More from COVID-19

More from Scrip